Biogen | BIIB - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
AbbVie USD 3.63B 54M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
Bayer EUR 3.7B 356M 2026-03
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
Incyte USD 351.73M 23.64M 2026-06
Merck USD 2.67B 180M 2026-03
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Sanofi EUR 2.49B 252M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06